```
=> d his ful

     (FILE 'REGISTRY' ENTERED AT 15:26:31 ON 26 AUG 2005)
                DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 15:39:34 ON 26 AUG 2005
L1           19 SEA ABB=ON  PLU=ON  LLGNSSPRTQSPQNC/SQSP

     FILE 'CAPLUS' ENTERED AT 15:39:52 ON 26 AUG 2005
L2           19 SEA ABB=ON  PLU=ON  L1
                D 1-19 .BEVSTR
                SEL HIT L2 1-19 RN

     FILE 'REGISTRY' ENTERED AT 15:40:53 ON 26 AUG 2005
L3           15 SEA ABB=ON  PLU=ON  (459618-22-5/BI OR 204463-85-4/BI OR
                104887-60-7/BI OR 188413-14-1/BI OR 465575-53-5/BI OR
                538461-38-0/BI OR 612121-58-1/BI OR 680651-90-5/BI OR
                786376-46-3/BI OR 818387-19-8/BI OR 845177-27-7/BI OR
                845212-20-6/BI OR 850701-51-8/BI OR 850701-61-0/BI OR
                850773-31-8/BI)
                D QUE
L4           15 SEA ABB=ON  PLU=ON  L1 AND L3
                D L3 1-15 .BEVREG1

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:41:20 ON 26 AUG 2005
L5            0 SEA ABB=ON  PLU=ON  L3

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:42:24 ON 26 AUG 2005

     FILE 'REGISTRY' ENTERED AT 15:42:38 ON 26 AUG 2005
                D L4 1-15 .BEVREG1

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:42:44 ON 26 AUG 2005
                D L5

     FILE 'HOME' ENTERED AT 15:42:44 ON 26 AUG 2005

     FILE 'HOME' ENTERED AT 15:42:58 ON 26 AUG 2005


     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    24 AUG 2005  HIGHEST RN 861772-82-9
     DICTIONARY FILE UPDATES:   24 AUG 2005  HIGHEST RN 861772-82-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ***************************************************************
     *                                                             *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
```

```
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMI for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

FILE CAPLUS

FILE COVERS 1907 - 26 Aug 2005 VOL 143 ISS 10
FILE LAST UPDATED: 25 Aug 2005 (20050825/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE
FILE LAST UPDATED: 25 AUG 2005 (20050825/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 25 August 2005 (20050825/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE
FILE COVERS 1974 TO 25 Aug 2005 (20050825/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HOME

Desai, A.
10/803541


```
FILE 'REGISTRY' ENTERED AT 15:39:34 ON 26 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    24 AUG 2005  HIGHEST RN 861772-82-9
DICTIONARY FILE UPDATES:   24 AUG 2005  HIGHEST RN 861772-82-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*******************************************************************
*                                                                 *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                 *
*******************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L1          19 LLGNSSPRTQSPQNC/SQSP

FILE 'CAPLUS' ENTERED AT 15:39:52 ON 26 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Aug 2005  VOL 143 ISS 10
FILE LAST UPDATED: 25 Aug 2005  (20050825/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
```

substance identification.

L2 19 L1

L2 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Apr 2005
ACCESSION NUMBER: 2005:371014 CAPLUS
DOCUMENT NUMBER: 142:424888
TITLE: Protein and cDNA sequences of human prelamin A and use in diagnosis and therapy of cardiac and skeletal muscle disorders
INVENTOR(S): Brodsky, Gary
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 55 pp. CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005090438	A1	20050428	US 2004-803541		20040317
PRIORITY APPLN. INFO.:			US 2003-456642P	P	20030318

AB Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing. The protein and cDNA sequences of human prelamin A are provided and site-directed mutagenesis are performed to construct prelamin A mutants: Arg60Gly, Leu85Arg, Asn195Lys, Glu203Gly, Arg89Leu and Arg377His. Mutations that cause dilated cardiomyopathy resulted in aberrant lamin A localization and lamina formation. The prelamin A protein containing the Glu203Gly mutation had a greater mobility than those containing the Arg89Leu and Arg377His mutations, demonstrating that the Glu203Gly mutation affects a different prelamin A processing step. Expression of fusion proteins containing the Asn195Lys, Glu203Gly, and Arg89Leu mutations resulted in aberrant myocyte morphol., both in myotubes expressing these mutant proteins, and in adjacent myotubes that do not express the fusion proteins.

IT **850701-51-8 850773-31-8**, Prelamin A (human)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein and cDNA sequences of human prelamin A and use in diagnosis and therapy of cardiac and skeletal muscle disorders)

IT **850701-61-0**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of human prelamin A and use in diagnosis and therapy of cardiac and skeletal muscle disorders)

L2 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Mar 2005
ACCESSION NUMBER: 2005:182700 CAPLUS
DOCUMENT NUMBER: 142:238661
TITLE: Gene expression profile in activated CD4-positive

```
                         T cells useful for the diagnosis and treatment of
                         immune-related diseases
INVENTOR(S):             Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun;
                         Williams, Mickey P.; Wood, William I.; Wu, Thomas
                         D.
PATENT ASSIGNEE(S):      Genentech, Inc., USA
SOURCE:                  PCT Int. Appl., 158 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  4
PATENT INFORMATION:

     PATENT NO.          KIND    DATE         APPLICATION NO.          DATE
     ---------------     ----    --------     --------------------     --------
     WO 2005019258        A2     20050303     WO 2004-US25788          20040810
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
             SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
             VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
             DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,
             PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
     WO 2005019258        A2     20050303     WO 2004-XA25788          20040810
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
             SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
             VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
             DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,
             PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                        US 2003-493546P      P   20030811

                                              WO 2004-US25788      A   20040810
```

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT **845212-20-6**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profile in activated CD4-pos.

T cells useful for the diagnosis and treatment of immune-related diseases)

L2 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Feb 2005
ACCESSION NUMBER: 2005:158694 CAPLUS
DOCUMENT NUMBER: 142:238660
TITLE: Gene expression profile in activated CD4-positive T cells useful for the diagnosis and treatment of immune-related diseases
INVENTOR(S): Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016962	A2	20050224	WO 2004-US26249	20040811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016962	A2	20050224	WO 2004-XA26249	20040811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-493546P P 20030811
WO 2004-US26249 A 20040811

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract

record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **845177-27-7**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; gene expression profile in activated CD4-pos. T cells useful for the diagnosis and treatment of immune-related diseases)

L2 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Feb 2005
ACCESSION NUMBER: 2005:156228 CAPLUS
Correction of: 2005:16967
DOCUMENT NUMBER: 142:192331
Correction of: 142:108390
TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 46
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005003394	A1	20050106	US 2004-812782		20040330
US 2004014059	A1	20040122	US 2002-268730		20021009
US 2004265869	A1	20041230	US 2004-812716		20040330
US 2005003394	A1	20050106	US 2004-812782		20040330
US 2005003394	A1	20050106	US 2004-812782		20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P	19990106
			US 2000-477148	B1	20000104
			US 2002-268730	A2	20021009
			US 2003-601518	A2	20030620
			US 2004-802875	A2	20040312
			US 2004-812782	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. expression of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific

and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

IT **459618-22-5**, Protein (human 515-amino acid)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; quant. RT-PCR method for detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state)

L2 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Jan 2005
ACCESSION NUMBER: 2005:16967 CAPLUS
DOCUMENT NUMBER: 142:108390
TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005003394 A1		20050106	US 2004-812782	20040330
PRIORITY APPLN. INFO.:			US 1999-PV115125	19990106
			US 2000-2000/477148	20000104
			US 2002-2002/268730	20021009
			US 2003-2003/601518	20030620
			US 2004-2004/802875	20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. expression of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

IT **459618-22-5**, Protein (human 515-amino acid)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; quant. RT-PCR method for detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state)

L2 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Jan 2005
ACCESSION NUMBER: 2005:9282 CAPLUS
DOCUMENT NUMBER: 142:88534
TITLE: HCV regulated proteins and anti-hepatitis C virus compounds
INVENTOR(S): Berndt, Peter; Kilby, Peter Michael; Rugman, Paul
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: Eur. Pat. Appl., 346 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1493750	A2	20050105	EP 2004-15098		20040628
EP 1493750	A3	20050209			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
CA 2469140	AA	20041230	CA 2004-2469140		20040625
JP 2005047895	A2	20050224	JP 2004-192804		20040630
PRIORITY APPLN. INFO.:			GB 2003-15248	A	20030630

AB The present invention relates to novel host cell targets for antiviral, preferably anti-hepatitis C virus (HCV), compds. identified by anal. of HCV replicon-regulated polypeptide expression, to prognostic markers for the prediction of the outcome of a viral infection, to in vitro methods for the prediction of the outcome of a HCV infection in a subject, to screening methods for identifying compds. which interact with and/or modulate the activity of the novel host cell targets or which modulate the expression of said novel host cell targets.

IT **818387-19-8**, Protein (human)
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; HCV regulated proteins and anti-hepatitis C virus compds.)

L2 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Nov 2004
ACCESSION NUMBER: 2004:978972 CAPLUS
DOCUMENT NUMBER: 142:49914
TITLE: The status, quality, and expansion of the NIH full-length cDNA project: The mammalian gene collection (MGC)
AUTHOR(S): Gerhard, Daniela S.; Wagner, Lukas; Feingold, Elise A.; Shenmen, Carolyn M.; Grouse, Lynette H.; Schuler, Greg; Klein, Steven L.; Old, Susan; Rasooly, Rebekah; Good, Peter; Guyer, Mark; Peck, Allicon M.; Derge, Jeffery G.; Lipman, David; Collins, Francis S.
CORPORATE SOURCE: The MGC Project Team, NIH, USA
SOURCE: Genome Research (2004), 14(10b), 2121-2127
CODEN: GEREFS; ISSN: 1088-9051
PUBLISHER: Cold Spring Harbor Laboratory Press

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The National Institutes of Health's Mammalian Gene Collection (MGC) project was designed to generate and sequence a publicly accessible cDNA resource containing a complete open reading frame (ORF) for every human and mouse gene. The project initially used a random strategy to select clones from a large number of cDNA libraries from diverse tissues. Candidate clones were chosen based on 5'-EST sequences, and then fully sequenced to high accuracy and analyzed by algorithms developed for this project. Currently, more than 11,000 human and 10,000 mouse genes are represented in MGC by at least one clone with a full ORF. The random selection approach is now reaching a saturation point, and a transition to protocols targeted at the missing transcripts is now required to complete the mouse and human collections. Comparison of the sequence of the MGC clones to reference genome sequences reveals that most cDNA clones are of very high sequence quality, although it is likely that some cDNAs may carry missense variants as a consequence of exptl. artifact, such as PCR, cloning, or reverse transcriptase errors. Recently, a rat cDNA component was added to the project, and ongoing frog (Xenopus) and zebrafish (Danio) cDNA projects were expanded to take advantage of the high-throughput MGC pipeline. The sequence data for the full-length clones from this study have been submitted to GenBank/EMBL/DDBJ under accession nos. BC000001-BC077073. [This abstr record is one of 39 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **786376-46-3**, GenBank AAH14507
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; status, quality, and expansion of the NIH full-length cDNA project and mammalian gene collection (MGC))

L2 ANSWER 8 OF 19 CAPLUS
ED Entered STN: 04 Jun 2004
ACCESSION NUMBER: 2004:449883 CAPLUS
DOCUMENT NUMBER: 140:402911
TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 886 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XA33946	20031024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,

```
            BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
            LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
            GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2004038376        A2    20040506   WO 2003-US33946        20031024
     WO 2004038376        A3    20040826
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
            GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
            MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
            SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
            YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
            NE, SN, TD, TG
PRIORITY APPLN. INFO.:                     US 2002-420729P     P  20021024

                                           US 2002-421062P     P  20021025

                                           US 2002-421102P     P  20021025

                                           US 2002-424701P     P  20021108

                                           US 2002-424715P     P  20021108

                                           US 2002-424718P     P  20021108

                                           US 2002-425256P     P  20021112

                                           US 2003-448461P     P  20030221

                                           US 2003-448462P     P  20030221

                                           US 2003-457877P     P  20030327

                                           US 2003-458373P     P  20030331

                                           WO 2003-US33946     A  20031024
```

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of expression of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal

predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assocs. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

IT **459618-22-5**, Protein (human 515-amino acid)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; binary prediction tree modeling with many predictors and its uses in clin. and genomic applications)

L2 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Apr 2004

ACCESSION NUMBER: 2004:355058 CAPLUS
DOCUMENT NUMBER: 140:333622
TITLE: Splice-site mutations in LMNA gene associated with Hutchinson-Gilford progeria syndrome and arteriosclerosis and diagnostic and therapeutic applications
INVENTOR(S): Eriksson, Maria B. H.; Collins, Francis S.; Gordon, Leslie B.; Brown, Ted W.
PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA; The Progeria Research Foundation, Inc.; New York State Office of Mental Retardation and Developmental Disabilities; Research Foundation For Mental Hygiene, Inc.
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035753	A2	20040429	WO 2003-US33058	20031017
WO 2004035753	A3	20041223		
WO 2004035753	B1	20050310		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

```
              NE, SN, TD, TG
     CA 2501464          AA     20040429    CA 2003-2501464        20031017
     EP 1552020          A2     20050713    EP 2003-809146         20031017
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
             PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2005059071       A1     20050317    US 2004-943400         20040917
PRIORITY APPLN. INFO.:                      US 2002-419541P     P  20021018

                                            US 2003-463084P     P  20030414

                                            WO 2003-US33058     W  20031017
```

AB Disclosed herein are point mutations in the LMNA gene that cause Hutchinson-Gilford progeria syndrome (HGPS) and arteriosclerosis. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is (50) amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these mols. in detecting biol. conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compds. that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compds. for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.

IT **680651-90-5**
RL: PRP (Properties)
(unclaimed protein sequence; splice-site mutations in LMNA gene associated with Hutchinson-Gilford progeria syndrome and arteriosclerosis and diagnostic and therapeutic applications)

L2 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Jan 2004

ACCESSION NUMBER: 2004:59653 CAPLUS
DOCUMENT NUMBER: 140:126701
TITLE: Cellular gene expression monitoring for human cytomegalovirus (HCMV) infection for diagnostic and drug screening applications
INVENTOR(S): Zhu, Hua; Gingeras, Thomas R.; Shenk, Thomas
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont. of U.S. Ser. No. 377,907.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004014027	A1	20040122	US 2001-950024		20010912
PRIORITY APPLN. INFO.:			US 1999-377907	A1	19990820

AB Certain human genes have been found to be induced or repressed in host cells infected with HCMV. A large set of such genes has been identified. These have diagnostic use in determining the extent of tissue damage caused by the infection as well as in determining the stage of disease progression of the HCMV infection. Such genes are likely those involved in mediating the pathol. of the infected tissues. Thus by identifying agents which are able to reverse the induction or repression of such genes, one can find candidate therapeutic agents for use in treating and or preventing HCMV-caused disease pathologies. Specifically disclosed are 258 mRNAs (with GenBank Accession Number provided) identified from microarray of about 6600 mRNA isolated from primary human fibroblast infected with HCMV strain AD169, whose levels are changed by a factor of 4 or more (124 increased, 134 decreased) in response to HCMV infection (after infection but before the onset of viral DNA replication). Several of these mRNAs are claimed to encode gene products that might play key roles in virus-induced pathogenesis, which include HLA-E, Ro/SSA, lipocortin-1, cPLA2, COX-2 and thrombospondin-1.

IT **459618-22-5**, Protein (human 515-amino acid)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; cellular gene expression monitoring for human cytomegalovirus (HCMV) infection for diagnostic and drug screening applications)

L2 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Nov 2003
ACCESSION NUMBER: 2003:875393 CAPLUS
DOCUMENT NUMBER: 139:363045
TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-US38221	20021112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

```
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
            BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
            MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
            GW, ML, MR, NE, SN, TD, TG
     WO 2003091391       A2    20031106   WO 2002-XB38221       20021112
        W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,
            CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
            MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
            BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
            MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
            GW, ML, MR, NE, SN, TD, TG
     US 2003224383       A1    20031204   US 2002-291885        20021112
PRIORITY APPLN. INFO.:                    US 2002-374547P     P 20020423

                                          US 2002-420784P     P 20021024

                                          US 2002-421043P     P 20021025

                                          US 2002-424680P     P 20021108

                                          WO 2002-US38221     A 20021112
```

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal.

IT **459618-22-5**, Protein (human 515-amino acid)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics)

L2 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Oct 2003
ACCESSION NUMBER: 2003:837371 CAPLUS
DOCUMENT NUMBER: 139:333132
TITLE: Targets for therapeutic intervention identified in the human mitochondrial proteome
INVENTOR(S): Ghosh, Soumitra S.; Fahy, Eoin D.; Zhang, Bing; Gibson, Bradford W.; Taylor, Steven W.; Glenn, Gary M.; Warnock, Dale E.
PATENT ASSIGNEE(S): Mitokor, USA; The Buck Institute for Age Research
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 2003087768         A2    20031023    WO 2003-US10870        20030404
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
             NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2004101874         A1    20040527    US 2003-408765         20030404
PRIORITY APPLN. INFO.:                       US 2002-372843P     P  20020412

                                             US 2002-389987P     P  20020617

                                             US 2002-412418P     P  20020920
```

AB Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences are provided for 3025 polypeptides that comprise the human heart mitochondrial proteome, using fractionated proteins derived from highly purified mitochondrial prepns., to identify previously unrecognized mitochondrial mol. components. Oxidative post-translational modification of tryptophan residues to N-formylkynurenine in cardiac mitochondrial proteins is also demonstrated by mass spectrometry.

IT **612121-58-1**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; targets for therapeutic intervention identified in the human mitochondrial proteome)

```
L2   ANSWER 13 OF 19  CAPLUS  COPYRIGHT 2005 ACS on STN
ED   Entered STN:  12 Jun 2003
ACCESSION NUMBER:        2003:448588  CAPLUS
                           Correction of: 2003:177121
DOCUMENT NUMBER:         139:18399
                           Correction of: 138:216593
TITLE:                   Differentially expressed nucleic acids and their
                         encoded proteins associated with pain and their
                         use in screening for regulatory agents
INVENTOR(S):             Woolf, Clifford; D'Urso, Donatella; Befort, Katia;
                         Costigan, Michael
PATENT ASSIGNEE(S):      The General Hospital Corporation, USA; Bayer AG
SOURCE:                  PCT Int. Appl., 1017 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  7
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 2003016475         A2    20030227    WO 2002-XB25765        20020814
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
```

CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
WO 2003016475 A2 20030227 WO 2002-US25765 20020814
WO 2003016475 A3 20040910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-312147P P 20010814

US 2001-346382P P 20011101

US 2001-333347P P 20011126

WO 2002-US25765 A 20020814

AB The present invention relates to human and rat nucleic acid sequences which are related to pain and which are differentially expressed during pain. The nucleic acids are differentially expressed by at least ±1.4-fold in any or all of the following conditions using the Affymetrix human U95, murine U74 and rat U34 GeneChip arrays: axotomy, spared nerve injury, chronic construction, spinal segmental nerve lesion, and inflammatory pain models. The invention further relates to methods of identifying nucleic acid sequences which are differentially expressed during pain, microarrays comprising such differentially expressed sequences, and methods of screening agents for the ability to regulate the expression of such differentially expressed sequences. [This abstract record is one of seven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **538461-38-0**
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; differentially expressed nucleic acids and their encoded proteins associated with pain and their use in screening for regulatory agents)

L2 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 May 2003
ACCESSION NUMBER: 2003:409169 CAPLUS
DOCUMENT NUMBER: 138:380506
TITLE: Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses

INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke, Martin; Lemke, Britt; Hacker, Christine
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer Molekulare Medizin
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003038130	A2	20030508	WO 2002-US34888	20021031
WO 2003038130	A3	20040212		
WO 2003038130	C1	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-335048P P 20011031
US 2001-335183P P 20011102
WO 2002-US34888 A 20021031

AB The present invention provides mol. targets that regulate erythropoiesis. Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an in vitro growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36+ progenitors, cord blood, or CD34+ peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. [This abstract record is one of two records for this document necessitated by the

large number of index entries required to fully index the document and publication system constraints.].

IT 459618-22-5, Protein (human 515-amino acid)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses)

L2 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Oct 2002
ACCESSION NUMBER: 2002:786973 CAPLUS
DOCUMENT NUMBER: 137:274808
TITLE: Translational profiling of human cell types by expressed peptide tags and global peptide tags
INVENTOR(S): Chicz, Roman M.; Tomlinson, Andrew J.; Urban, Robert G.
PATENT ASSIGNEE(S): Zycos, Inc., USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002078524	A2	20021010	WO 2002-US9671		20020328
WO 2002078524	A3	20041125			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004236091	A1	20041125	US 2004-473127		20040617
PRIORITY APPLN. INFO.:			US 2001-279495P	P	20010328
			US 2001-292544P	P	20010521
			US 2001-310801P	P	20010808
			US 2001-326370P	P	20011001
			US 2001-336780P	P	20011204
			US 2002-358985P	P	20020220
			WO 2002-US9671	W	20020328

AB Two hundred thirty-five peptides representative of proteins expressed by a given human cell type and isolated nucleic acids that encode the polypeptides are disclosed. Thus, peptides are identified by immunoaffinity purification of class I and class I HLA mols., followed by acid extraction and solid phase extraction of the EPT (expressed protein tag)

repertoire, reversed phase HPLC separation and mass spectrometry anal. Enzymic or chemical digestion strategies to reduce proteins of a complex mixture yields peptides designated global peptide tags (GPT), which are then separated and fractionated by multiple modes of chromatog. and ultimately sequenced by liquid chromatog. online with tandem mass spectrometry. Each peptide is classified according to cell line and HLA type, source protein reference(s), and a function key corresponding to biol. classification(s) such as kinases, phosphatases, proteases and protease inhibitors, transporters, cytoskeletal proteins, receptors, and transcription factors. The compns. and method described can be used to define a cell type at a given developmental, metabolic, or disease stage by identifying and cataloging proteins expressed in the cell. The compns. can also be used in the manufacture of therapeutics as well as in diagnostics and drug screening.

IT **465575-53-5**
RL: PRP (Properties)
(unclaimed protein sequence; translational profiling of human cell types by expressed peptide tags and global peptide tags)

L2 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Apr 2001
ACCESSION NUMBER: 2001:265589 CAPLUS
DOCUMENT NUMBER: 134:309238
TITLE: Human genes which expression is responsive to shear stress, the cDNA and protein sequences, and their use for developing drugs for vascular diseases
INVENTOR(S): Nojima, Hiroshi; Yoshisue, Hajime; Obayashi, Masaya; Ota, Toshio; Kawabata, Ayako; Sakurada, Kazuhiro; Kuga, Tetsuro; Sekine, Susumu; Nakamura, Yusuke; Sugano, Sumio
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 678 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025427	A1	20010412	WO 2000-JP6840	20001002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000074523	A5	20010510	AU 2000-74523	20001002
EP 1225224	A1	20020724	EP 2000-963041	20001002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-280976 A 19991001
WO 2000-JP6840 W 20001002

AB A series of human genes which expression is responsive to shear stress have been identified. Some (28) of these genes are novel and some (55) already known. The cDNA sequences and their protein sequences are disclosed. Also described are the antibodies against these proteins; a method of detecting a shear stress-responsive DNA or protein; remedies and diagnostics for vascular diseases caused by arteriosclerosis; and a method of screening a drug for treating or diagnosing these diseases. Methods for detecting apoptosis-inhibiting activity by using the primers derived from clone A4RS-041 was also described.

IT **204463-85-4**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human genes which expression is responsive to shear stress, cDNA and protein sequences, and use for developing drugs for vascular diseases)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Mar 1998
ACCESSION NUMBER: 1998:163759 CAPLUS
DOCUMENT NUMBER: 128:228247
TITLE: Tumor-associated proteins for development of immunoassays for detecting cervical cancer
INVENTOR(S): Keesee, Susan K.; Obar, Robert; Wu, Ying-Jye
PATENT ASSIGNEE(S): Matritech, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9809170	A2	19980305	WO 1997-US14526		19970819
WO 9809170	A3	19980423			
W: AU, CA, JP					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US 5858683	A	19990112	US 1996-705660		19960830
CA 2263888	AA	19980305	CA 1997-2263888		19970819
CA 2263888	C	20041026			
AU 9740732	A1	19980319	AU 1997-40732		19970819
EP 923740	A2	19990623	EP 1997-938400		19970819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001500609	T2	20010116	JP 1998-511706		19970819
US 6027905	A	20000222	US 1997-989045		19971211
US 2003157482	A1	20030821	US 1999-315355		19990517
US 6803189	B2	20041012			
US 2005164313	A1	20050728	US 2004-848572		20040518
PRIORITY APPLN. INFO.:			US 1996-705660	A	19960830
			WO 1997-US14526	W	19970819

US 1997-989045 A3 19971211

US 1999-315355 A1 19990517

AB The invention provides a wide range of methods and compns. for detecting and treating cervical cancer in an individual. Specifically, the invention provides target cervical cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of cervical cancer. The target cervical cancer-associated protein, may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cervical cancer in an individual. In addition, the invention provides methods utilizing the cervical cancer-associated proteins either as targets for treating cervical cancer or as indicators for monitoring of the efficacy of such a treatment.

IT **204463-85-4**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; tumor-associated proteins for development of immunoassays for detecting cervical cancer)

L2 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Mar 1997

ACCESSION NUMBER:	1997:142715 CAPLUS
DOCUMENT NUMBER:	126:248112
TITLE:	In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease
AUTHOR(S):	Kilic, Fusun; Dalton, Marguerite B.; Burrell, Sarah K.; Mayer, John P.; Patterson, Scott D.; Sinensky, Michael
CORPORATE SOURCE:	Department of Biochemistry and Molecular Biology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614-0581, USA
SOURCE:	Journal of Biological Chemistry (1997), 272(8), 5298-5304 CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER:	American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The 72-kDa nuclear lamina protein lamin A is synthesized as a 74-kDa farnesylated precursor. Conversion of this precursor to mature lamin A appears to be mediated by a specific endoprotease. Prior studies of overexpressed wild-type and mutant lamin A proteins in cultured cells have indicated that the precursor possesses the typical carboxyl-terminal S-farnesylated, cysteine Me ester and that farnesylation is required for endoproteolysis to occur. In this report, we describe the synthesis of an S-farnesyl, cysteinyl Me ester peptide corresponding to the carboxyl-terminal 18 amino acid residues of human prelamin A. This peptide acts as a substrate for the prelamin A endoprotease in vitro, with cleavage of the synthetic peptide at the expected site between Tyr657 and Leu658. Endoproteolytic cleavage requires the S-prenylated cysteine Me ester and, in agreement with transfection studies, is more active with the farnesylated than geranylgeranylated cysteinyl substrate. N-Acetyl farnesyl Me cysteine is shown to be a noncompetitive inhibitor of the enzyme. Taken together, these observations suggest that there is a

specific farnesyl binding site on the enzyme which is not at the active site.

IT **188413-14-1**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(in vitro assay and characterization of farnesylation-dependent prelamin A endoprotease)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Nov 1986
ACCESSION NUMBER: 1986:585075 CAPLUS
DOCUMENT NUMBER: 105:185075
TITLE: cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins
AUTHOR(S): Fisher, Daniel Z.; Chaudhary, Nilabh; Blobel, Guenter
CORPORATE SOURCE: Lab. Cell Biol., Rockefeller Univ., New York, NY, 10021, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1986), 83(17), 6450-4
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The amino acid sequences deduced from cDNA clones of human lamin A and lamin C show identity between these 2 lamins except for an extra 9.0-kilodalton C-terminal tail that is present only in lamin A. Both lamins A and C contain an α-helical domain of ≈360 residues that shows striking homol. to a corresponding α-helical rod domain that is the structural hallmark of all intermediate filament proteins. However, the lamin α-helical domain is 14% larger than that of the intermediate filament proteins. In addition to the extensive homol. to intermediate filament proteins, a different 82-amino-acid residue stretch at the C terminus of lamin A was deduced and verified by amino acid sequencing. This region contains sequence homol. to N- and C-terminal domains of type I and type II epidermal keratins. Implications of the presence of these and other domains in lamins A and C for the assembly of the nuclear lamina are discussed.

IT **104887-60-7**
RL: PRP (Properties)
(amino acid sequence of)

E1 THROUGH E15 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:40:53 ON 26 AUG 2005
L3 15 SEA FILE=REGISTRY ABB=ON PLU=ON (459618-22-5/BI OR 204463-85-4/BI OR 104887-60-7/BI OR 188413-14-1/BI OR 465575-53-5/BI OR 538461-38-0/BI OR 612121-58-1/BI OR 680651-90-5/BI OR 786376-46-3/BI OR 818387-19-8/BI OR 845177-27-7/BI OR 845212-20-6/BI OR 850701-51-8/BI OR 850701-61-0/BI OR 850773-31-8/BI)

L4 15 L1 AND L3

L4 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN

```
RN   850773-31-8  REGISTRY
CN   Prelamin A (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   4: PN: US20050090438 SEQID: 4 claimed protein
CI   MAN
SQL  664

SEQ      1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
        51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
       101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
       151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
       201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
       251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
       301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
       351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
       401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
       451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
       501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
       551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
       601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                         ====
       651 SSPRTQSPQN CSIM
           ========== =
HITS AT:   647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:424888

L4   ANSWER 2 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   850701-61-0  REGISTRY
CN   L-Methionine, L-leucyl-L-leucylglycyl-L-asparaginyl-L-seryl-L-seryl-L-
     prolyl-L-arginyl-L-threonyl-L-glutaminyl-L-seryl-L-prolyl-L-glutaminyl-
     L-asparaginyl-L-cysteinyl-L-seryl-L-isoleucyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   20: PN: US20050090438 SEQID: 20 unclaimed sequence
SQL  18

SEQ      1 LLGNSSPRTQ SPQNCSIM
           ========== =====
HITS AT:   1-15

REFERENCE   1:  142:424888

L4   ANSWER 3 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   850701-51-8  REGISTRY
CN   L-Cysteine, L-leucyl-L-leucylglycyl-L-asparaginyl-L-seryl-L-seryl-L-
     prolyl-L-arginyl-L-threonyl-L-glutaminyl-L-seryl-L-prolyl-L-glutaminyl-
     L-asparaginyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2: PN: US20050090438 SEQID: 2 claimed sequence
CN   prelamin A (human fragment)
SQL  15

SEQ      1 LLGNSSPRTQ SPQNC
           ========== =====
HITS AT:   1-15

REFERENCE   1:  142:424888
```

```
L4   ANSWER 4 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845212-20-6  REGISTRY
CN   Immune disease-associated protein PRO95041 (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   779: PN: WO2005019258 SEQID: 882 claimed protein
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                        ====
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  142:238661

L4   ANSWER 5 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   845177-27-7  REGISTRY
CN   Immune disease-associated protein PRO95041 (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   779: PN: WO2005016962 SEQID: 882 claimed protein
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                        ====
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661
```

```
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  142:238660

L4    ANSWER 6 OF 15   REGISTRY   COPYRIGHT 2005 ACS on STN
RN    818387-19-8   REGISTRY
CN    Protein (human) (9CI)   (CA INDEX NAME)
OTHER NAMES:
CN    44: PN: EP1493750 SEQID: 44 claimed protein
CI    MAN
SQL   664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                         ====
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  142:88534

L4    ANSWER 7 OF 15   REGISTRY   COPYRIGHT 2005 ACS on STN
RN    786376-46-3   REGISTRY
CN    Lamin A/C, isoform 1 precursor (human clone MGC:23638 IMAGE:4863480
      gene LMNA) (9CI)   (CA INDEX NAME)
OTHER NAMES:
CN    GenBank AAH14507
CN    GenBank AAH14507 (Translated from: GenBank BC014507)
CI    MAN
SQL   664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                         ====
        651 SSPRTQSPQN CSIM
```

```
          ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  142:49914

L4   ANSWER 8 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   680651-90-5  REGISTRY
CN   2: PN: WO2004035753 SEQID: 2 unclaimed protein (9CI)  (CA INDEX NAME)
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                              ====
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  140:333622

L4   ANSWER 9 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   612121-58-1  REGISTRY
CN   Protein (human heart clone GenBank gi:14750186 mitochondria-
     associated) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2079: PN: WO03087768 SEQID: 2079 claimed protein
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                              ====
        651 SSPRTQSPQN CSIM
```

```
         ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:   139:333132

L4   ANSWER 10 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   538461-38-0  REGISTRY
CN   Pain-regulated protein (human clone WO03016475-SEQID-9921) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   2822: PN: WO03016475 SEQID: 9921 claimed protein
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                              ====
        651 SSPRTQSPQN CSIM
         ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:   139:18399

L4   ANSWER 11 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   465575-53-5  REGISTRY
CN   1423: PN: WO02078524 SEQID: 1658 unclaimed protein (9CI)  (CA INDEX
     NAME)
CI   MAN
SQL  664

SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                              ====
```

```
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  137:274808

L4   ANSWER 12 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   459618-22-5  REGISTRY
CN   Protein (human 515-amino acid) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1838: PN: WO2004038376 TABLE: 5 unclaimed protein
CN   237: PN: US20050003394 TABLE: 3M claimed protein
CN   3640: PN: WO03091391 FIGURE: 20 unclaimed protein
CN   582: PN: WO03038130 FIGURE: 3 claimed protein
CN   GenBank AAA36160
CN   GenBank AAA36160 (Translated from: GenBank M13452)
CI   MAN
SQL  515

SEQ      1 TALSEKRTLE GELHDLRGQV AKLEAALGEA KKQLQDEMLR RVDAENRLQT
        51 MKEELDFQKN IYSEELRETK RRHETRLVEI DNGKQREFES RLADALQELR
       101 AQHEDQVEQY KKELEKTYSA KLDNARQSAE RNSNLVGAAH EELQQSRIRI
       151 DSLSAQLSQL QKQLAAKEAK LRDLEDSLAR ERDTSRRLLA EKEREMAEMR
       201 ARMQQQLDEY QELLDIKLAL DMEIHAYRKL LEGEEERLRL SPSPTSQRSR
       251 GRASSHSSQT QGGGSVTKKR KLESTESRSS FSQHARTSGR VAVEEVDEEG
       301 KFVRLRNKSN EDQSMGNWQI KRQNGDDPLL TYRFPPKFTL KAGQVVTIWA
       351 AGAGATHSPP TDLVWKAQNT WGCGNSLRTA LINSTGEEVA MRKLVRSVTV
       401 VEDDEDEDGD DLLHHHHGSH CSSSGDPAEY NLRSRTVLCG TCGQPADKAS
       451 ASGSGAQVGG PISSGSSASS VTVTRSYRSV GGSGGGSFGD NLVTRSYLLG
                                                          ===
       501 NSSPRTQSPQ NCSIM
           ========== ==
HITS AT:    498-512

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE    1:  142:192331

REFERENCE    2:  142:108390

REFERENCE    3:  140:402911

REFERENCE    4:  140:126701

REFERENCE    5:  139:363045

REFERENCE    6:  138:380506

L4   ANSWER 13 OF 15  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   204463-85-4  REGISTRY
CN   Lamin A (human fibroblast C-terminal fragment) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   16: PN: WO0125427 SEQID: 40 unclaimed protein
CN   Protein (human 515-amino acid)
CI   MAN
SQL  515
```

```
SEQ       1 TALSEKRTLE GELHDLRGQV AKLEAALGEA KKQLQDEMLR RVDAENRLQT
         51 MKEELDFQKN IYSEELRETK RRHETRLVEI DNGKQREFES RLADALQELR
        101 AQHEDQVEQY KKELEKTYSA KLDNARQSAE RNSNLVGAAH EELQQSRIRI
        151 DSLSAQLSQL QKQLAAKEAK LRDLEDSLAR ERDTSRRLLA EKEREMAEMR
        201 ARMQQQLDEY QELLDIKLAL DMEIHAYRKL LEGEEERLRL SPSPTSQRSR
        251 GRASSHSSQT QGGGSVTKKR KLESTESRSS FSQHARTSGR VAVEEVDEEG
        301 KFVRLRNKSN EDQSMGNWQI KRQNGDDPLL TYRFPPKFTL KAGQVVTIWA
        351 AGAGATHSPP TDLVWKAQNT WGCGNSLRTA LINSTGEEVA MRKLVRSVTV
        401 VEDDEDEDGD DLLHHHHGSH CSSSGDPAEY NLRSRTVLCG TCGQPADKAS
        451 ASGSGAQVGG PISSGSSASS VTVTRSYRSV GGSGGGSFGD NLVTRSYLLG
                                                          ===
        501 NSSPRTQSPQ NCSIM
            ========== ==
HITS AT:    498-512
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:309238

REFERENCE 2: 128:228247

L4 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN

RN **188413-14-1** REGISTRY

CN L-Cysteine, L-arginyl-L-seryl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-asparaginyl-L-seryl-L-seryl-L-prolyl-L-arginyl-L-threonyl-L-glutaminyl-L-seryl-L-prolyl-L-glutaminyl-L-asparaginyl-S-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-, methyl ester (9CI) (CA INDEX NAME)

SQL 18

```
SEQ       1 RSYLLGNSSP RTQSPQNC
               ======= ========
HITS AT:    4-18
```

REFERENCE 1: 126:248112

L4 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN

RN **104887-60-7** REGISTRY

CN Lamin A (human precursor protein moiety reduced) (9CI) (CA INDEX NAME)

CI MAN

SQL 664

```
SEQ       1 METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR
         51 SLETENAGLR LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA
        101 RLQLELSKVR EEFKELKARN TKKEGDLIAA QARLKDLEAL LNSKEAALST
        151 ALSEKRTLEG ELHDLRGQVA KLEAALGEAK KQLQDEMLRR VDAENRLQTM
        201 KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR LADALQELRA
        251 QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
        301 SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA
        351 RMQQQLDEYQ ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG
        401 RASSHSSQTQ GGGSVTKKRK LESTESRSSF SQHARTSGRV AVEEVDEEGK
        451 FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT YRFPPKFTLK AGQVVTIWAA
        501 GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM RKLVRSVTVV
        551 EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
        601 SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN
                                                         ====
        651 SSPRTQSPQN CSIM
            ========== =
HITS AT:    647-661
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 105:185075

FILE 'MEDLINE' ENTERED AT 15:42:44 ON 26 AUG 2005

FILE 'BIOSIS' ENTERED AT 15:42:44 ON 26 AUG 2005

FILE 'EMBASE' ENTERED AT 15:42:44 ON 26 AUG 2005

L5 0 S L3

=> fil hom
FILE 'HOME' ENTERED AT 15:42:58 ON 26 AUG 2005